Evaluating the impact of Mexico’s drug policy reforms on people who inject drugs in Tijuana, B.C., Mexico, and San Diego, CA, United States: a binational mixed methods research agenda

Harm Reduction Journal

Steffanie A Strathdee²  Patricia Gonzalez Moreno-Zuniga²  Jazmine Cuevas-Mota²  Carlos Magis-Rodriguez³  Sanjay R Mehta¹  Karla D Wagner²  Richard S Garfein²  Angela M Robertson⁴ 

[1] Division of Infectious Diseases, School of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0711, USA;Division of Global Public Health, School of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0507, USA;Centro Nacional para la Prevención y Control del VIH y el SIDA, Secretaría de Salud de México, México;The Fenway Institute, Fenway Health, 1340 Boylston St, 8th floor, Boston, MA 02215, USA

关键词: Mexico;    International collaboration;    Mixed methods;    Decriminalization;    Structural interventions;    Drug policy reform;    M. tuberculosis;    Hepatitis C virus;    HIV;    Injection drug use;   

Others  :  809725
DOI  :  10.1186/1477-7517-11-4

 received in 2013-10-16, accepted in 2014-01-10,  发布年份 2014

【 摘 要 】

Background

Policymakers and researchers seek answers to how liberalized drug policies affect people who inject drugs (PWID). In response to concerns about the failing “war on drugs,” Mexico recently implemented drug policy reforms that partially decriminalized possession of small amounts of drugs for personal use while promoting drug treatment. Recognizing important epidemiologic, policy, and socioeconomic differences between the United States—where possession of any psychoactive drugs without a prescription remains illegal—and Mexico—where possession of small quantities for personal use was partially decriminalized, we sought to assess changes over time in knowledge, attitudes, behaviors, and infectious disease profiles among PWID in the adjacent border cities of San Diego, CA, USA, and Tijuana, Baja California, Mexico.

Methods

Based on extensive binational experience and collaboration, from 2012–2014 we initiated two parallel, prospective, mixed methods studies: Proyecto El Cuete IV in Tijuana (n = 785) and the STAHR II Study in San Diego (n = 575). Methods for sampling, recruitment, and data collection were designed to be compatible in both studies. All participants completed quantitative behavioral and geographic assessments and serological testing (HIV in both studies; hepatitis C virus and tuberculosis in STAHR II) at baseline and four semi-annual follow-up visits. Between follow-up assessment visits, subsets of participants completed qualitative interviews to explore contextual factors relating to study aims and other emergent phenomena. Planned analyses include descriptive and inferential statistics for quantitative data, content analysis and other mixed-methods approaches for qualitative data, and phylogenetic analysis of HIV-positive samples to understand cross-border transmission dynamics.

Results

Investigators and research staff shared preliminary findings across studies to provide feedback on instruments and insights regarding local phenomena. As a result, recruitment and data collection procedures have been implemented successfully, demonstrating the importance of binational collaboration in evaluating the impact of structural-level drug policy reforms on the behaviors, health, and wellbeing of PWID across an international border.

Conclusions

Our prospective, mixed methods approach allows each study to be responsive to emerging phenomena within local contexts while regular collaboration promotes sharing insights across studies. The strengths and limitations of this approach may serve as a guide for other evaluations of harm reduction policies internationally.

【 授权许可】

   
2014 Robertson et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]The Vienna Declaration [http://www.viennadeclaration.com webcite]
• [2]Degenhardt L, Chiu W-T, Sampson N, Kessler RC, Anthony JC, Angermeyer M, Bruffaerts R, de Girolamo G, Gureje O, Huang Y, Karam A, Kostyuchenko S, Lepine JP, Medina Mora ME, Neumark Y, Ormel JH, Pinto-Meza A, Posada-Villa J, Stein DJ, Takeshima T, Wells JE: Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008, 5:e141.
• [3]Lurie P, Drucker E: An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 1997, 349:604-608.
• [4]Rhodes T, Lowndes C, Judd A, Mikhailova LA, Sarang A, Rylkov A, Tichonov M, Lewis K, Ulyanova N, Alpatova T, Karavashkin V, Khutorskoy M, Hickman M, Parry JV, Renton A: Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS 2002, 16:F25-F31.
• [5]Davis CS, Burris S, Kraut-Becher J, Lynch KG, Metzger D: Effects of an intensive street-level police intervention on syringe exchange program use in Philadelphia, PA. Am J Public Health 2005, 95:233-236.
• [6]Bluthenthal RN, Kral AH, Lorvick J, Watters JK: Impact of law enforcement on syringe exchange programs: a look at Oakland and San Francisco. Med Anthropol 1997, 18:61-83.
• [7]Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M: Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010, 376:285-301.
• [8]Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A, Strathdee SA: HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-1028.
• [9]Ahern J, Stuber J, Galea S: Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend 2007, 88:188-196.
• [10]Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA: The social structural production of HIV risk among injecting drug users. Soc Sci Med 2005, 61:1026-1044.
• [11]Sarang A, Rhodes T, Platt L, Kirzhanova V, Shelkovnikova O, Volnov V, Blagovo D, Rylkov A: Drug injecting and syringe use in the HIV risk environment of Russian penitentiary institutions: qualitative study. Addiction 2006, 101:1787-1796.
• [12]Jurgens R, Ball A, Verster A: Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 2009, 9:57-66.
• [13]Elliott R, Csete J, Palepu A, Kerr T: Reason and rights in global drug control policy. CMAJ 2005, 172:655-656.
• [14]Edwards G, Babor T, Darke S, Hall W, Marsden J, Miller P, West R: Drug trafficking: time to abolish the death penalty. Addiction 2009, 104:1267-1269.
• [15]United Nations Office on Drugs and Crime: World Drug Report 2012. In World Drug Report 2012. Vienna: UNODC; 2012. [http://www.unodc.org webcite]
• [16]Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Kazatchkine M, Sidibe M, Strathdee SA: Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 2010, 376:551-563.
• [17]Wood E, Werb D, Marshall BDL, Montaner JSG, Kerr T: The war on drugs: a devastating public-policy disaster. Lancet 2009, 373:989-990.
• [18]Wood E, Werb D, Kazatchkine M, Kerr T, Hankins C, Gorna R, Nutt D, Des Jarlais D, Barre-Sinoussi F, Montaner J: Vienna Declaration: a call for evidence-based drug policies. Lancet 2010, 376:310-312.
• [19]Reuter P: Ten years after the United Nations General Assembly Special Session (UNGASS): assessing drug problems, policies and reform proposals. Addiction 2009, 104:510-517.
• [20]European Monitoring Centre for Drugs and Drug Addiction: Illicit Drug Use in the EU: Legislative Approaches. In Illicit Drug Use in the EU: legislative approaches. Lisbon: EMCDDA; 2005. [http://www.emcdda.europa.eu/eldd webcite]
• [21]Cozac D: Rulings in Argentinean and Colombian courts decriminalize possession of small amounts of narcotics. HIV AIDS Policy Law Rev 2009, 14:54-55.
• [22]International Drug Policy Consortium: IDPC Drug Policy Guide. IDPC Drug Policy Guide 2012. [http://idpc.net webcite]
• [23]Rolles S, Kushlick D, Jay M: After the War on Drugs, Options for Control. In After the War on Drugs, Options for Control. Bristol: Transform Drug Policy Foundation; 2006. [http://www.tdpf.org.uk webcite]
• [24]Hughes C, Stevens A: The Effects of Decriminalization of Drug Use in Portugal. In The effects of decriminalization of drug use in Portugal. Beckley Foundation Drug Policy Programme; 2007. [http://www.idpc.net webcite]
• [25]Russoniello K: The devil (and drugs) in the details: Portugal's focus on public health as a model for decriminalization of drugs in Mexico. Yale J Health Policy Law Ethics 2012, 12:371-431.
• [26]Moreno JG, Licea JA, Ajenjo CR: Tackling HIV and drug addiction in Mexico. Lancet 2010, 376:493-495.
• [27]Comision Nacional contra las Adicciones (National Council Against Addiction): Normatividad y legislación: consejo nacional contras las adicciones (National legislation against addiction). 2010. [http://www.conadic.salud.gob.mx webcite]
• [28]Celentano D, Beyrer C: Public Health Aspects of HIV/AIDS in Low and Middle Income Countries: Epidemiology, Prevention and Care. New York; London: Springer; 2008.
• [29]Strathdee SA, Magis-Rodriguez C: Mexico's evolving HIV epidemic. JAMA 2008, 300:571-573.
• [30]Volkow P, Marin Lopez A, Torres I: Plasma trade and the HIV epidemic. Lancet 1997, 349:327-328.
• [31]Centro Nacional Para la Prevencion y el Control de VIH/SIDA (National Center for HIV Prevention): El SIDA en Mexico: estadisticas (AIDS in Mexico: statistics). 2009. [http://www.censida.salud.gob.mx webcite]
• [32]Brouwer KC, Case P, Ramos R, Magis-Rodriguez C, Bucardo J, Patterson TL, Strathdee SA: Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico. Subst Use Misuse 2006, 41:707-727.
• [33]Bucardo J, Brouwer KC, Magis-Rodriguez C, Ramos R, Fraga M, Perez SG, Patterson TL, Strathdee SA: Historical trends in the production and consumption of illicit drugs in Mexico: implications for the prevention of blood borne infections. Drug Alcohol Depend 2005, 79:281-293.
• [34]Ciccarone D, Bourgois P: Explaining the geographical variation of HIV among injection drug users in the United States. Subst Use Misuse 2003, 38:2049-2063.
• [35]Comision Nacional contra las Adicciones (National Council Against Addiction): Encuesta nacional de adicciones 2008 (National survey on addictions 2008). 2008. [http://www.conadic.salud.gob.mx webcite]
• [36]Iniguez-Stevens E, Brouwer KC, Hogg RS, Patterson TL, Lozada R, Magis-Rodriguez C, Elder JP, Viani RM, Strathdee SA: Estimaciones de Prevalencia del VIH por Género y Grupo de Riesgo en Tijuana, México: 2006 [Estimating the 2006 prevalence of HIV by gender and risk groups in Tijuana, Mexico]. Gac Med Mex 2009, 145:189-195.
• [37]Strathdee SA, Lozada R, Semple SJ, Orozovich P, Pu M, Staines-Orozco H, Fraga-Vallejo M, Amaro H, Delatorre A, Magis-Rodriguez C, Patterson TL: Characteristics of female sex workers with US clients in two Mexico-US border cities. Sex Transm Dis 2008, 35:263-268.
• [38]Frost SDW, Brouwer KC, Firestone Cruz MA, Ramos R, Ramos ME, Lozada RM, Magis-Rodriguez C, Strathdee SA: Respondent-driven sampling of injection drug users in two U.S.-Mexico border cities: recruitment dynamics and impact on estimates of HIV and syphilis prevalence. J Urban Health 2006, 83:83-97.
• [39]White EF, Garfein RS, Brouwer KC, Lozada R, Ramos R, Firestone-Cruz M, Perez SG, Magis-Rodriguez C, Conde-Glez CJ, Strathdee SA: Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud Publica Mex 2007, 49:165-172.
• [40]Garfein RS, Laniado-Laborin R, Gallardo M, Lozada R, Barnes RF, Rodwell TC, Cuevas-Mota J, Vera A, Burgos JL, Strathdee SA: Injection Drug Users at High Risk for Incident M. Tuberculosis Infection in Tijuana, Mexico. 17th Conference on Retroviruses and Opportunistic Infections (March 16–19, 2010)[http://www.croi2014.org webcite]
• [41]Garfein RS, Laniado-Laborin R, Rodwell TC, Lozada R, Deiss R, Burgos JL, Cuevas-Mota J, Cerecer P, Moser K, Volker ML, Strathdee SA: Latent tuberculosis among persons at risk for infection with HIV, Tijuana, Mexico. Emerg Infect Dis 2010, 16:757-763.
• [42]McShane H: Co-infection with HIV and TB: double trouble. Int J STD AIDS 2005, 16:95-9100.
• [43]Cruz MF, Mantsios A, Ramos R, Case P, Brouwer KC, Ramos ME, Fraga WD, Latkin CA, Miller CL, Strathdee SA: A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities. AIDS Behav 2007, 11:253-262.
• [44]Strathdee SA, Fraga WD, Case P, Firestone M, Brouwer KC, Perez SG, Magis C, Fraga MA: "Vivo para consumirla y la consumo para vivir" ["I live to inject and inject to live"]: high-risk injection behaviors in Tijuana, Mexico. J Urban Health 2005, 82:58-73.
• [45]Miller CL, Firestone M, Ramos R, Burris S, Ramos ME, Case P, Brouwer KC, Fraga MA, Strathdee SA: Injecting drug users' experiences of policing practices in two Mexican-U.S. border cities: public health perspectives. Int J Drug Policy 2008, 19:324-331.
• [46]Syvertsen J, Pollini RA, Lozada R, Vera A, Rangel G, Strathdee SA: Managing la malilla: Exploring drug treatment experiences among injection drug users in Tijuana, Mexico, and their implications for drug law reform. Int J Drug Policy 2010, 21:459-465.
• [47]Rusch ML, Lozada R, Pollini RA, Vera A, Patterson TL, Case P, Strathdee SA: Polydrug use among IDUs in Tijuana, Mexico: correlates of methamphetamine use and route of administration by gender. J Urban Health 2009, 86:760-775.
• [48]Des Jarlais DC, Paone D, Friedman SR, Peyser N, Newman RG: Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs. Am J Public Health 1995, 85:1577-1584.
• [49]Friedman SR, Cooper HL, Tempalski B, Keem M, Friedman R, Flom PL, Des Jarlais DC: Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS 2006, 20:93-99.
• [50]Rhodes T, Mikhailova L, Sarang A, Lowndes CM, Rylkov A, Khutorskoy M, Renton A: Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. Soc Sci Med 2003, 57:39-54.
• [51]Wood E, Spittal PM, Small W, Kerr T, Li K, Hogg RS, Tyndall MW, Montaner JSG, Schechter MT: Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ 2004, 170:1551-1556.
• [52]Beletsky L, Lozada R, Gaines T, Abramovitz D, Staines H, Vera A, Rangel G, Arredondo J, Strathdee SA: Syringe confiscation as an HIV risk factor: the public health implications of arbitrary policing in Tijuana and Ciudad Juarez, Mexico. J Urban Health 2012, 90:284-298.
• [53]Strathdee SA, Lozada R, Ojeda VD, Pollini RA, Brouwer KC, Vera A, Cornelius W, Nguyen L, Magis-Rodriguez C, Patterson TL: Differential effects of migration and deportation on HIV infection among male and female injection drug users in Tijuana, Mexico. PLoS One 2008, 3:e2690.
• [54]Strathdee SA, Lozada R, Pollini RA, Brouwer KC, Mantsios A, Abramovitz DA, Rhodes T, Latkin CA, Loza O, Alvelais J, Magis-Rodriguez C, Patterson TL: Individual, social, and environmental influences associated with HIV infection among injection drug users in Tijuana, Mexico. J Acquir Immune Defic Syndr 2008, 47:369-376.
• [55]Volkmann T, Lozada R, Anderson CM, Patterson TL, Vera A, Strathdee SA: Factors associated with drug-related harms related to policing in Tijuana. Harm Reduct J 2011, 8:7. BioMed Central Full Text
• [56]Pollini RA, Brouwer KC, Lozada RM, Ramos R, Cruz MF, Magis-Rodriguez C, Case P, Burris S, Pu M, Frost SDW, Palinkas LA, Miller C, Strathdee SA: Syringe possession arrests are associated with receptive syringe sharing in two Mexico-US border cities. Addiction 2008, 103:101-108.
• [57]Robertson AM, Vera AY, Gallardo M, Pollini RA, Patterson TL, Case P, Nguyen L, Strathdee SA: Correlates of seeking injection assistance among injection drug users in Tijuana, Mexico. Am J Addict 2010, 19:357-363.
• [58]Pollini RA, Lozada R, Gallardo M, Rosen P, Vera A, Macias A, Palinkas LA, Strathdee SA: Barriers to pharmacy-based syringe purchase among injection drug users in Tijuana, Mexico: a mixed methods study. AIDS Behav 2010, 14:679-687.
• [59]Davidson PJ, Lozada R, Rosen PC, Macias A, Gallardo M, Pollini RA: Negotiating access: social barriers to purchasing syringes at pharmacies in Tijuana, Mexico. Int J Drug Policy 2012, 23:286-294.
• [60]Riley ED, Kral AH, Stopka TJ, Garfein RS, Reuckhaus P, Bluthenthal RN: Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. J Urban Health 2010, 87:534-542.
• [61]Wagner KD, Moynihan MJ, Strathdee SA, Cuevas-Mota J, Clark M, Zuniga ML, Volkmann TA, Teshale E, Garfein RS: The social and environmental context of cross-border drug use in Mexico: findings from a mixed methods study of young injection drug users living in San Diego, CA. J Ethn Subst Abuse 2012, 11:362-378.
• [62]Instituto Nacional de Estadistica Geografia e Informatica (INEGI): Resultados definitivos del II conteo de población y vivienda 2005 para Tijuana, Baja California (Definitive results of 2010 census for Tijuana, Baja California). 2010. [http://www.inegi.org.mx webcite]
• [63]Clemens MA, Montenegro CE, Pritchett L: The Place Premium: Wage Differences for Identical Workers Across the U.S. Border. 2009. [Havard Kennedy School (Working Paper No. RWP09-004) and Center for Global Development (Working Paper No. 148)] [http://dx.doi.org/10.2139/ssrn.1211427 webcite]
• [64]Garfein RS, Rondinelli A, Barnes RF, Cuevas J, Metzner M, Velasquez M, Rodriguez D, Reilly M, Xing J, Teshale EH: HCV infection prevalence lower than expected among 18-40-year-old injection drug users in San Diego, CA. J Urban Health 2012, 90(3):516-528.
• [65]Garfein RS, Lozada R, Liu L, Laniado-Laborin R, Rodwell TC, Deiss R, Alvelais J, Catanzaro A, Chiles PG, Strathdee SA: High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico. Int J Tuberc Lung Dis 2009, 13:626-632.
• [66]Hammett TM, Des Jarlais DC, Kling R, Kieu BT, McNicholl JM, Wasinrapee P, McDougal JS, Liu W, Chen Y, Meng D, Doan N, Huu Nguyen T, Hoang QN, Hoang TV: Controlling HIV epidemics among injection drug users: eight years of cross-border HIV prevention interventions in Vietnam and China. PLoS One 2012, 7:e43141.
• [67]Des Jarlais DC, Johnston P, Friedmann P, Kling R, Liu W, Ngu D, Chen Y, Hoang TV, Donghua M, Van LK, Tung ND, Binh KT, Hammett TM: Patterns of HIV prevalence among injecting drug users in the cross-border area of Lang Son Province, Vietnam, and Ning Ming County, Guangxi Province. BMC Public Health 2005, 5:89. BioMed Central Full Text
• [68]Beyrer C, Razak MH, Lisam K, Chen J, Lui W, Yu XF: Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS 2000, 14:75-83.
• [69]Korf DJ: Dutch coffee shops and trends in cannabis use. Addict Behav 2002, 27:851-866.
• [70]Uriely N, Belhassen Y: Drugs and risk-taking in tourism. Ann Tourism Res 2006, 33:339-359.
• [71]de Guzman GC, Khaleghi M, Riffenberg RH, Clark RF: A survey of the use of foreign-purchased medications in a border community emergency department patient population. J Emerg Med 2007, 33:213-221.
• [72]Ornes L, Hendrix TJ: Prescription drug re-importation: a balanced look. J Gerontol Nurs 2006, 32:15-19.
• [73]Rivera JO, Ortiz M, Cardenas V: Cross-border purchase of medications and health care in a sample of residents of El Paso, Texas, and Ciudad Juarez, Mexico. J Natl Med Assoc 2009, 101:167-173.
• [74]Volkmann T, Shin SS, Garfein RS, Patterson TL, Pollini RA, Wagner KD, Artamanova I, Strathdee SA: Border crossing to inject drugs in Mexico among injection drug users in San Diego, California. J Immigr Minor Health 2012, 14:281-286.
• [75]Brouwer KC, Lozada R, Cornelius WA, Firestone Cruz M, Magis-Rodriguez C, de Nuncio ML Z, Strathdee SA: Deportation along the U.S.-Mexico border: its relation to drug use patterns and accessing care. J Immigr Minor Health 2009, 11:1-6.
• [76]Wagner KD, Pollini RA, Patterson TL, Lozada R, Ojeda VD, Brouwer KC, Vera A, Volkmann TA, Strathdee SA: Cross-border drug injection relationships among injection drug users in Tijuana, Mexico. Drug Alcohol Depend 2011, 113:236-241.
• [77]Rhodes T: The 'risk environment': a framework for understanding and reducing drug-related harm. Int J Drug Policy 2002, 13:85-94.
• [78]Rogers E: Diffusion of Innovations. New York, NY: Free Press; 1995.
• [79]Valente T: Evaluating Health Promotion Programs. Oxford: Oxford University Press; 2002.
• [80]Watters JK, Biernacki P: Targeted sampling: options for the study of hidden populations. Social Problems 1989, 36:416-430.
• [81]Guba EG, Lincoln YS: Fourth Generation Evaluation. Newbury Park, CA: Sage Publications; 1989.
• [82]Guest G: How many interviews are enough?: An experiment with data saturation and variability. Field Methods 2006, 18:59-82.
• [83]Creswell JW: Research Design: Qualitative, Quantitative, and Mixed Methods Approaches. 3rd edition. Thousand Oaks, CA: Sage Publications; 2009.
• [84]Case P, Ramos R, Brouwer KC, Firestone-Cruz M, Pollini RA, Fraga MA, Patterson TL, Strathdee SA: At the borders, on the edge: use of injected methamphetamine in Tijuana and Ciudad Juarez, Mexico. J Immigr Minor Health 2008, 10:23-33.
• [85]Perlman DC, Henman AR, Kochems L, Paone D, Salomon N, Des Jarlais DC: Doing a shotgun: a drug use practice and its relationship to sexual behaviors and infection risk. Soc Sci Med 1999, 48:1441-1448.
• [86]Cohen R, Muzaffar S, Capellan J, Azar H, Chinikamwala M: The validity of classic symptoms and chest radiographic configuration in predicting pulmonary tuberculosis. Chest 1996, 109:420-423.
• [87]Mackinnon DP, Dwyer JH: Estimating mediated effects in prevention studies. Eval Rev 1993, 17:144-158.
• [88]Smith DM, May SJ, Tweeten S, Drumright L, Pacold ME, Kosakovsky Pond SL, Pesano RL, Lie YS, Richman DD, Frost SD, Woelk CH, Little SJ: A public health model for the molecular surveillance of HIV transmission in San Diego,. AIDS 2009, 23:225-232.
• [89]MacQueen KM, McLellan E, Kay K, Milstein B: Codebook development for team-based qualitative analysis. Field Methods 1998, 10:31-36.
• [90]Willms DG, Best JA, Taylor DW, Gilbert JR, Wilson DMC, Lindsay EA, Singer J: A systematic approach for using qualitative methods in primary prevention research. Med Anthropol Q 1990, 4:391-409.
• [91]Teddlie C, Tashakkori A: Major Issues and Controversies in the Use of Mixed Methods in the Social and Behavioral Sciences. In Handbook of Mixed Methods in the Social and Behavioral Sciences. Thousand Oaks, CA: Sage; 2003.
• [92]Sale JM, Lohfeld L, Brazil K: Revisiting the quantitative-qualitative debate: implications for mixed-methods research. Quality & Quantity 2002, 36:43-53.
• [93]Kelle U: Sociological explanations between micro and macro and the integration of qualitative and quantitative methods. Historical Social Research 2005, 30:95-117.
• [94]Cresswell J, Plano Clark V: Designing and Conducting Mixed Method Research. Thousand Oaks: Sage; 2007.
• [95]Angen MJ: Evaluating interpretive inquiry: reviewing the validity debate and opening the dialogue. Qual Health Res 2000, 10:378-395.
• [96]Corbin JM, Strauss AL: Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. 3rd edition. Los Angeles, CA: Sage Publications, Inc.; 2008.
• [97]Wagner KD, Davidson PJ, Pollini RA, Strathdee SA, Washburn R, Palinkas LA: Reconciling incongruous qualitative and quantitative findings in mixed methods research: Exemplars from research with drug using populations. Int J Drug Policy 2011, 23:54-61.
• [98]Woolley CM: Meeting the mixed methods challenge of integration in a sociological study of structure and agency. Journal of Mixed Methods Research 2009, 3:7-25.
• [99]Slonim-Nevo V, Nevo I: Conflicting findings in mixed methods research: an illustration from an Israeli study on immigration. Journal of Mixed Methods Research 2009, 3:109-128.
• [100]Darke S, Hall W, Heather N, Ward J, Wodak A: The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS 1991, 5:181-185.
• [101]De Irala J, Bigelow C, McCusker J, Hindin R, Zheng L: Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol 1996, 143:725-732.
• [102]Van Duynhoven YT, Nagelkerke NJ, Van De Laar MJ: Reliability of self-reported sexual histories: test-retest and interpartner comparison in a sexually transmitted diseases clinic. Sex Transm Dis 1999, 26:33-42.